|
[1]
|
McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022;22(10):1435 − 43. http://dx.doi.org/10.1016/S1473-3099(22)00345-0CrossRef
|
|
[2]
|
Huang ZY, Xu SF, Liu JC, Wu LL, Qiu J, Wang N, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022;20(1):400. http://dx.doi.org/10.1186/s12916-022-02606-8CrossRef
|
|
[3]
|
Rodewald L, Wu D, Yin ZD, Feng ZJ. Vaccinate with confidence and finish strong. China CDC Wkly 2022;4(37):828 − 31. http://dx.doi.org/10.46234/ccdcw2022.172CrossRef
|
|
[4]
|
Kwok SLL, Cheng SMS, Leung JNS, Leung K, Lee CK, Peiris JM, et al. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill 2022;27(2):2101197. http://dx.doi.org/10.2807/1560-7917.ES.2022.27.2.2101197CrossRef
|
|
[5]
|
Zeng G, Wu QH, Pan HX, Li MJ, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 2022;22(4):483 − 95. http://dx.doi.org/10.1016/S1473-3099(21)00681-2CrossRef
|
|
[6]
|
Xin QQ, Wu QH, Chen XH, Han BH, Chu K, Song Y, et al. Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nat Commun 2022;13(1):3100. http://dx.doi.org/10.1038/s41467-022-30864-wCrossRef
|
|
[7]
|
Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021;398(10298):385 − 7. http://dx.doi.org/10.1016/S0140-6736(21)01642-1CrossRef
|
|
[8]
|
Jacobsen H, Katzmarzyk M, Higdon MM, Jiménez VC, Sitaras I, Bar-Zeev N, et al. Post-vaccination neutralization responses to Omicron sub-variants. Vaccines 2022;10(10):1757. http://dx.doi.org/10.3390/vaccines10101757CrossRef
|
|
[9]
|
Juno JA, Wheatley AK. Boosting immunity to COVID-19 vaccines. Nat Med 2021;27(11):1874 − 5. http://dx.doi.org/10.1038/s41591-021-01560-xCrossRef
|
|
[10]
|
Zhao X, Li DD, Ruan WJ, Chen ZH, Zhang R, Zheng AQ, et al. Effects of a prolonged booster interval on neutralization of omicron variant. N Engl J Med 2022;386(9):894 − 6. http://dx.doi.org/10.1056/NEJMc2119426CrossRef
|
|
[11]
|
Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis 2022;226(8):1372 − 81. http://dx.doi.org/10.1093/infdis/jiac092CrossRef
|
|
[12]
|
Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, et al. Six-month follow-up after a fourth BNT162b2 vaccine dose. N Engl J Med 2022;387(22):2092 − 4. http://dx.doi.org/10.1056/NEJMc2211283CrossRef
|
|
[13]
|
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med 2022;386(18):1712 − 20. http://dx.doi.org/10.1056/NEJMoa2201570CrossRef
|
|
[14]
|
Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ 2022;377:e071113. http://dx.doi.org/10.1136/bmj-2022-071113CrossRef
|